• Results for the Second Quarter and First Half 2019

    Q2 2019 is the third consecutive quarter with strong growth in both sales revenues and EBIT; 23.1 % and 70.4 % respectively.  Read the full report and presentation below. Medistim Q2 19 presentation 2.quarter 2019

    Read more
  • Results for the First Quarter 2019

    Sales in the first quarter amounted to MNOK 88.7 (MNOK 74.1), a 19.7 % growth. Of the MNOK 14.6 in sales growth, MNOK 11.6 was from the US, where the sales increase in NOK was…

    Read more
  • Annual Report 2018

    During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…

    Read more
  • Results for Fourth Quarter and Preliminary Results for Medistim for 2018

    Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4),…

    Read more
  • Results for the Third Quarter 2018

    Sales as of September increased by 4.0 % and ended at MOK 228.0 (MNOK 219.2). Revenue from own products showed a currency neutral decline of 0.4 % for the quarter and a currency neutral growth…

    Read more
  • REQUEST Final Results: Strengthening the Recommendation for Medistim’s Dual Technology

    The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and Transit Time Flow Measurement (TTFM) performed with Medistim's VeriQ C or MiraQ devices will change the…

    Read more
  • Results for the Second Quarter 2018

    Sales for the first half of 2018 increased by 4,7 % and ended at MNOK 150,4 (MNOK 143,5). Currency neutral growth of own products was 19,3 % for the second quarter. Operating profit (EBIT) ended…

    Read more
  • REQUEST Interim Results: Significant Impact on Surgical Strategy with Medistim’s Devices

    The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and transit time flow measurement (TTFM) performed with Medistim’s VeriQ C or MiraQ devices will change the…

    Read more
  • Results for the First Quarter 2018

    Currency neutral sales of own products decreased with 2.7 %. Operating profit (EBIT) ended at MNOK 13.6 (MNOK 16.0). Medistims equipment received an updated recommendation by NICE in UK. Data collection in the REQUEST study…

    Read more
  • Annual Report 2017

    We have further strengthened our position within cardiac bypass surgery, in particular in our most important market USA, where we now have achieved a market penetration of 20% measured as the share of bypass procedures…

    Read more